New data presented at the 2025 World Congress of Pediatric Dermatology annual meeting highlights the efficacy and safety of ...

A decade-long study finds that obesity is associated with a significantly increased risk for biologic treatment failure in ...

The favorable data provided support for two ongoing phase III, randomized, placebo-controlled trials of ESK-001 in ...

Icotrokinra is efficacious and safe for treating moderate to severe plaque psoriasis among adolescents and adults when compared with placebo.

ORLANDO, Fla. — In moderate to severe plaque psoriasis, two highly selective oral TYK2 inhibitors produced a level of response in phase 2 studies suggesting that drugs in this class might rival ...

Recent study findings highlight the value of integrating behavioral modification and Health Belief Model–based education into ...

(RTTNews) - Johnson & Johnson (JNJ) announced new icotrokinra (JNJ-2113) data from its Phase 3 clinical program and the start of the first-ever head-to-head study in plaque psoriasis (PsO ...